Adenosine receptors as therapeutic targets for the treatment of myocardial infarction and its complications. Part II. Post-myocardial infarction heart failure and arrhythmias

1. Ibáñez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocar-dial ischemia/reperfusion injury. J Am Coll Cardiol 2015;65(14):1454-71.10.1016/j.jacc.2015.02.03225857912Search in Google Scholar

2. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: Mechanisms, incidence and identification of patients at risk. World J Cardiol 2017;9(5):407-15.10.4330/wjc.v9.i5.407544240828603587Search in Google Scholar

3. Greene SJ, Sabbah HN, Butler J, Voors AA, Albrecht-Küpper BE, Düngen HD, et al. Partial adenosine A₁ receptor agonism: a potential new therapeutic strategy for heart failure. Heart Fail Rev 2016;21(1):95-102.10.1007/s10741-015-9522-726701329Search in Google Scholar

4. Heusch G, Gersh BJ. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. Eur Heart J 2017;38(11):774-84.Search in Google Scholar

5. Da Silva JS, Gabriel-Costa D, Sudo RT, Wang H, Groban L, Ferraz EB, et al. Adenosine A₂A receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction. Drug Des Devel Ther 2017;11:553-62.10.2147/DDDT.S113289534599728293100Search in Google Scholar

6. Jackson G, Gibbs CR, Davies MK, Lip GY. ABC of heart failure. Pathophysiology. BMJ 2000;320(7228):167-70.10.1136/bmj.320.7228.167112874710634740Search in Google Scholar

7. Puhl SL, Kazakov A, Müller A, Fries P, Wagner DR, Böhm M, et al. Adeno-sine A₁ receptor activation attenuates cardiac hypertrophy and fibrosis in response to α1-adrenoceptor stimulation in vivo. Br J Pharmacol 2016;173(1):88-102.10.1111/bph.13339481337926406609Search in Google Scholar

8. Pang T, Gan XT, Freeman DJ, Cook MA, Karmazyn M. Compensatory upregulation of the adenosine system following phenylephrine -induced hyper-trophy in cultured rat ventricular myocytes. Am J Physiol Heart Circ Physiol 2010;298(2):H545-53.10.1152/ajpheart.00417.200919966059Search in Google Scholar

9. Liao Y, Takashima S, Asano Y, Asakura M, Ogai A, Shintani Y, et al. Activation of adenosine A₁ receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure -overload model. Circ Res 2003;93(8):759-66.10.1161/01.RES.0000094744.88220.6212970111Search in Google Scholar

10. Lu Z, Fassett J, Xu X, Hu X, Zhu G, French J, et al. Adenosine A₃ receptor deficiency exerts unanticipated protective effects on the pressure -overloaded left ventricle. Circulation 2008;118(17):1713-21.10.1161/CIRCULATIONAHA.108.788307280305018838560Search in Google Scholar

11. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, et al. Chronic therapy with a partial adenosine A₁ -receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 2013;6(3):563-71.10.1161/CIRCHEARTFAILURE.112.000208379014123564604Search in Google Scholar

12. Dinh W, Albrecht-Küpper B, Gheorghiade M, Voors AA, van der Laan M, Sabbah HN. Partial adenosine A₁ agonist in heart failure. Handb Exp Pharmacol 2017;243:177-203.10.1007/164_2016_8327770217Search in Google Scholar

13. Baltos JA, Vecchio EA, Harris MA, Qin CX, Ritchie RH, Christopoulos A, et al. Capadenoson, a clinically trialed partial adenosine A₁ receptor agonist, can stimulate adenosine A_2B receptor biased agonism. Biochem Pharmacol 2017;135:79-89.10.1016/j.bcp.2017.03.01428344125Search in Google Scholar

14. Meibom D, Albrecht-Küpper B, Diedrichs N, Hübsch W, Kast R, Krämer T, et al. Neladenoson bialanate hydrochloride: a prodrug of a partial aden-osine A₁ receptor agonist for the chronic treatment of heart diseases. ChemMedChem 2017;12(10):728-37.10.1002/cmdc.20170015128488817Search in Google Scholar

15. Voors AA, Düngen HD, Senni M, Nodari S, Agostoni P, Ponikowski P, et al. Safety and tolerability of neladenoson bialanate, a novel oral partial aden-osine A₁ receptor agonist, in patients with chronic heart failure. J Clin Pharmacol 2017;57(4):440-51.10.1002/jcph.82827624622Search in Google Scholar

16. Da Silva JS, Pereira SL, Maia Rdo C, Landgraf SS, Caruso -Neves C, Küm-merle AE, et al. N -acylhydrazone improves exercise intolerance in rats submitted to myocardial infarction by the recovery of calcium homeostasis in skeletal muscle. Life Sci 2014;94(1):30-6.10.1016/j.lfs.2013.11.01224269214Search in Google Scholar

17. Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, et al. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace 2014;16(11):1655-73.10.1093/europace/euu20825172845Search in Google Scholar

18. Bhar-Amato J, Davies W, Agarwal S. Ventricular arrhythmia after acute myocardial infarction: ‘The perfect storm’. Arrhythm Electrophysiol Rev 2017;6(3):134-9.10.15420/aer.2017.24.1561073129018522Search in Google Scholar

19. Azevedo PS, Polegato BF, Minicucci MF, Paiva SA, Zornoff LA. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment. Arq Bras Cardiol 2016;106(1):62-9.10.5935/abc.20160005472859726647721Search in Google Scholar

20. Francis Stuart SD, De Jesus NM, Lindsey ML, Ripplinger CM. The crossroads of inflammation, fibrosis, and arrhythmia following myocardial infarction. J Mol Cell Cardiol 2016;91:114-212.10.1016/j.yjmcc.2015.12.024476439526739214Search in Google Scholar

21. Szentmiklosi AJ, Galajda Z, Cseppento Á, Gesztelyi R, Susán Z, Hegyi B, et al. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. Curr Pharm Des 2015;21(8):965-76.10.2174/138161282066614102910034625354187Search in Google Scholar

22. Lerman BB. Ventricular tachycardia: mechanistic insights derived from adenosine. Circ Arrhythm Electrophysiol 2015;8(2):483-91.10.1161/CIRCEP.115.00169325900991Search in Google Scholar

23. Zhang H, Zhong H, Everett TH 4th, Wilson E, Chang R, Zeng D, et al. Blockade of A_2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm 2014;11(1):101-9.10.1016/j.hrthm.2013.10.02324120874Search in Google Scholar

24. Vecchio EA, White PJ, May LT. Targeting adenosine receptors for the treatment of cardiac fibrosis. Front Pharmacol 2017;8:243.10.3389/fphar.2017.00243541834028529484Search in Google Scholar

25. Wakeno M, Minamino T, Seguchi O, Okazaki H, Tsukamoto O, Okada K, et al. Long -term stimulation of adenosine A_2B receptors begun after myocardial infarction prevents cardiac remodeling in rats. Circulation 2006;114(18):1923-32.10.1161/CIRCULATIONAHA.106.63008717043167Search in Google Scholar

26. Toldo S, Zhong H, Mezzaroma E, Van Tassell BW, Kannan H, Zeng D, et al. GS-6201, a selective blocker of the A_2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther 2012;343(3):587-95.10.1124/jpet.111.19128822923737Search in Google Scholar